default author photo

Yongping Song

Zhengzhou University - Affiliated Cancer Hospital

Zhengzhou, Henan

China

SCHOLARLY PAPERS

1

DOWNLOADS

81

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Sintilimab for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial (ORIENT-4)

Number of pages: 22 Posted: 09 Apr 2020
Shanghai Jiao Tong University (SJTU), School of Medicine, Xin Hua Hospital, Department of Hematology, Nanjing Medical University - Collaborative Innovation Center for Cancer Personalized Medicine, Zhengzhou University - Affiliated Cancer Hospital, Huazhong University of Science and Technology - Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Tianjin Medical University - Cancer Institute and Hospital, Innovent Biologics (Suzhou) Co. Ltd, Innovent Biologics (Suzhou) Co. Ltd, Innovent Biologics (Suzhou) Co. Ltd, Nanjing Medical University - Collaborative Innovation Center for Cancer Personalized Medicine and Shanghai University - Institute of ADR and Arbitration
Downloads 81 (796,622)

Abstract:

Loading...

Extranodal NK/T-cell lymphoma; PD-1; relapse; refractory; sintilimab